FY2024 EPS Estimates for Theratechnologies Inc. Lifted by Analyst (NASDAQ:THTX)

Theratechnologies Inc. (NASDAQ:THTX) – Stock analysts at Cantor Fitzgerald raised their FY2024 earnings estimates for shares of Theratechnologies in a research note issued on Friday, October 11th. Cantor Fitzgerald analyst L. Chen now expects that the company will earn $0.04 per share for the year, up from their prior estimate of $0.02. The consensus estimate for Theratechnologies’ current full-year earnings is ($0.02) per share.

Theratechnologies (NASDAQ:THTX) last announced its earnings results on Thursday, October 10th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03. The firm had revenue of $22.60 million during the quarter. During the same period in the previous year, the business earned ($0.03) EPS.

Theratechnologies Stock Up 4.3 %

THTX opened at $1.30 on Monday. The company’s 50-day moving average price is $1.27 and its 200 day moving average price is $1.33. Theratechnologies has a fifty-two week low of $0.88 and a fifty-two week high of $2.58. The firm has a market cap of $59.77 million, a price-to-earnings ratio of -6.84 and a beta of 1.41.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.